Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday, March 2, 2026 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 46th Annual Health Care Conference Tuesday, March 3, 2026 2:30 p.m. ET - Prahlad Singh, president and chief executive officer Barclays 28th Annual Global Healthcare Conference Tuesday, March 10,.

Business Wire • Feb 17, 2026

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation,.

Business Wire • Feb 5, 2026

Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results

Revvity Inc. (NYSE: RVTY) on Monday reported better-than-expected earnings for the fourth quarter.

Benzinga • Feb 3, 2026

Here's Why Revvity (RVTY) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 3, 2026

Revvity: Close To A Buy, Not Quite There

Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.

Seeking Alpha • Feb 3, 2026

Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics business even as weakness in academic research funding persists.

Reuters • Feb 2, 2026

Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript

Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 2, 2026

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for t.

Business Wire • Feb 2, 2026

Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers

Revvity Inc. (NYSE: RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.

Benzinga • Feb 2, 2026

Revvity (RVTY) Q4 Earnings and Revenues Beat Estimates

Revvity (RVTY) came out with quarterly earnings of $1.7 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.42 per share a year ago.

Zacks Investment Research • Feb 2, 2026